본문 바로가기
KERD
논문KCI 등재

Update on heart failure management and future directions

박명수|윤종찬|최홍미
대한내과학회 (The Korean Association Of Internal Medicine)|2019.01|The Korean Journal of Internal Medicine|제34권 제1호|pp. 11-43|DOI https://doi.org/10.3904/kjim.2018.428

2

조회

0

다운로드

26

인용

0

참고문헌

키워드

ManagementDiagnosisPrognosisHeart failure
주제분류내과학

초록

Heart failure (HF) is an important cardiovascular disease because of its increasing prevalence, significant morbidity, high mortality, and rapidly expanding health care cost. The number of HF patients is increasing worldwide, and Korea is no exception. There have been marked advances in definition, diagnostic modalities, and treatment of HF over the past four decades. There is continuing effort to improve risk stratification of HF using biomarkers, imaging and genetic testing. Newly developed medications and devices for HF have been widely adopted in clinical practice. Furthermore, definitive treatment for end-stage heart failure including left ventricular assist device and heart transplantation are rapidly evolving as well. This review summarizes the current state-of-the-art management for HF and the emerging diagnostic and therapeutic modalities to improve the outcome of HF patients.

Abstract

Heart failure (HF) is an important cardiovascular disease because of its increasing prevalence, significant morbidity, high mortality, and rapidly expanding health care cost. The number of HF patients is increasing worldwide, and Korea is no exception. There have been marked advances in definition, diagnostic modalities, and treatment of HF over the past four decades. There is continuing effort to improve risk stratification of HF using biomarkers, imaging and genetic testing. Newly developed medications and devices for HF have been widely adopted in clinical practice. Furthermore, definitive treatment for end-stage heart failure including left ventricular assist device and heart transplantation are rapidly evolving as well. This review summarizes the current state-of-the-art management for HF and the emerging diagnostic and therapeutic modalities to improve the outcome of HF patients.

참고문헌 (204)

  1. Ponikowski P, "2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure : the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)developed with the special contribution of the Heart Failure Association(HFA)of the ESC", Eur Heart J, 37, pp.2129~2200 (2016)
  2. 김민석, "Korean Guidelines for Diagnosis and Management of Chronic Heart Failure", Korean Circulation Journal, 47(5), pp.555~643 (2017), 대한심장학회[DOI]
  3. 윤종찬, "Temporal Trends of Hospitalized Patients with Heart Failure in Korea", Korean Circulation Journal, 47(1), pp.16~24 (2017), 대한심장학회
  4. Rastogi A, "Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction", Eur J Heart Fail, 19, pp.1597~1605 (2017)
  5. Mosterd A, "Clinical epidemiology of heart failure", Heart, 93, pp.1137~1146 (2007)
  6. Owan TE, "Trends in prevalence and outcome of heart failure with preserved ejection fraction", N Engl J Med, 355, pp.251~259 (2006)
  7. Jung Hoon Lee, "Epidemiology of Heart Failure in Korea: Present and Future", Korean Circulation Journal, 46(5), pp.658~664 (2016), 대한심장학회
  8. Roberts E, "The diagnostic accuracy of the natriuretic peptides in heart failure : systematic review and diagnostic meta-analysis in the acute care setting", BMJ, 350, pp.h910~ (2015)
  9. SPRINT Research Group, "A randomized trial of intensive versus standard blood-pressure control", N Engl J Med, 373, pp.2103~2116 (2015)
  10. Curtis JP, "The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure", J Am Coll Cardiol, 42, pp.736~742 (2003)
  11. Meta-analysis Global Group in Chronic Heart Failure(MAGGIC), "The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction : an individual patient data meta-analysis", Eur Heart J, 33, pp.1750~1757 (2012)
  12. Zakeri R, "Heart failure with preserved ejection fraction : controversies, challenges and future directions", Heart, 104, pp.377~384 (2018)
  13. Potter E, "Assessment of left ventricular function by echocardiography : the case for routinely adding global longitudinal strain to ejection fraction", JACC Cardiovasc Imaging, 11, pp.260~274 (2018)
  14. Park JJ, "Global longitudinal strain to predict mortality in patients with acute heart failure", J Am Coll Cardiol, 71, pp.1947~1957 (2018)
  15. Ersboll M, "Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction", J Am Coll Cardiol, 61, pp.2365~2373 (2013)
  16. Plana JC, "Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy : a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging", J Am Soc Echocardiogr, 27, pp.911~939 (2014)
  17. Greyson CR, "Pathophysiology of right ventricular failure", Crit Care Med, 36, pp.S57~S65 (2008)
  18. de Groote P, "Right ventricular systolic function in heart failure : a long story but still the same question", Arch Cardiovasc Dis, 109, pp.227~230 (2016)
  19. Tadic M, "Right ventricular strain in heart failure : clinical perspective", Arch Cardiovasc Dis, 110, pp.562~571 (2017)
  20. Iacoviello M, "Right ven tricular longitudinal strain measures independently predict chronic heart failure mortality", Echocardiography, 33, pp.992~1000 (2016)
  21. Park JH, "Prognostic value of biventricular strain in risk stratifying in patients with acute heart failure", J Am Heart Assoc, 7, pp.e009331~ (2018)
  22. Farsalinos KE, "Head-to-head comparison of global longitudinal strain measurements among nine different vendors : the EACVI", ASE inter-vendor comparison study, 2015, pp.28, 1171~1181
  23. Schelbert EB, "State of the art : clinical applications of cardiac T1 mapping", Radiology, 278, pp.658~676 (2016)
  24. Mascherbauer J, "Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction", Circ Cardiovasc Imaging, 6, pp.1056~1065 (2013)
  25. Youn JC, "Contrast-enhanced T1mapping-based extracellular volume fraction independently predicts clinical outcome in patients with non-ischemic dilated cardiomyopathy : a prospective cohort study", Eur Radiol, 27, pp.3924~3933 (2017)
  26. Puntmann VO, "Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy", JACC Cardiovasc Imaging, 6, pp.475~484 (2013)
  27. Puntmann VO, "T1-mapping and outcome in nonischemic cardiomyopathy : allcause mortality and heart failure", JACC Cardiovasc Imaging, 9, pp.40~50 (2016)
  28. Lee HJ, "Myocardial extracellular volume fraction with dual-energy equilibrium contrast-enhanced cardiac CT in nonischemic cardiomyopathy : a prospective comparison with cardiac MR imaging", Radiology, 280, pp.49~57 (2016)
  29. Lee HJ, "Assessment of myocardial delayed enhancement with cardiac computed tomography in cardiomyopathies : a prospective comparison with delayed enhancement cardiac magnetic resonance imaging", Int J Cardiovasc Imaging, 33, pp.577~584 (2017)
  30. Chang S, "Utility of dual-energy CTbased monochromatic imaging in the assessment of myocardial delayed enhancement in patients with cardiomyopathy", Radiology, 287, pp.442~451 (2018)
  31. Ohta Y, "Myocardial delayed enhancement CT for the evaluation of heart failure : comparison to MRI", Radiology, 288, pp.682~691 (2018)
  32. Vliegenthart R, "Dual-energy CT of the heart", AJR Am J Roentgenol, 199, pp.S54~S63 (2012)
  33. Yancy CW, "2017 ACC expert consensus decision pathway for optimization of heart failure treatment : answers to 10 pivotal issues about heart failure with reduced ejection fraction : a report of the American College of Cardiology task force on expert consensus decision pathways", J Am Coll Cardiol, 71, pp.201~230 (2018)
  34. de Boer RA, "State of the art : newer biomarkers in heart failure", Eur J Heart Fail, 17, pp.559~569 (2015)
  35. Lassus J, "Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure : the Multinational Observational Cohort on Acute Heart Failure(MOCA)study", Int J Cardiol, 168, pp.2186~2194 (2013)
  36. Breidthardt T, "Heart failure therapy-induced early ST2 changes may offer longterm therapy guidance", J Card Fail, 19, pp.821~828 (2013)
  37. Bayes-Genis A, "Soluble ST2 serum concentration and renal function in heart failure", J Card Fail, 19, pp.768~775 (2013)
  38. 김민석, "Role of Soluble ST2 as a Prognostic Marker in Patients with Acute Heart Failure and Renal Insufficiency", Journal of Korean Medical Science, 30(5), pp.569~575 (2015), 대한의학회
  39. Gehlken C, "Galectin-3 in heart failure : an update of the last 3 years", Heart Fail Clin, 14, pp.75~92 (2018)
  40. Braunwald E, "Biomarkers in heart failure", N Engl J Med, 358, pp.2148~2159 (2008)
  41. Jackson CE, "The incremental prognostic and clinical value of multiple novel biomarkers in heart failure", Eur J Heart Fail, 18, pp.1491~1498 (2016)
  42. Januzzi JL, "Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management", Circulation, 127, pp.500~507 (2013)
  43. Savarese G, "Natriuretic peptide-guided therapy in chronic heart failure : a meta-analysis of 2, 686 patients in 12 randomized trials", PLoS One, 8, pp.e58287~ (2013)
  44. Felker GM, "Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction : a randomized clinical trial", JAMA, 318, pp.713~720 (2017)
  45. Roth GA, "Use of guideline-directed medications for heart failure before cardioverter-defibrillator implantation", J Am Coll Cardiol, 67, pp.1062~1069 (2016)
  46. 이상언, "Clinical Characteristics and Outcome of Acute Heart Failure in Korea: Results from the Korean Acute Heart Failure Registry (KorAHF)", Korean Circulation Journal, 47(3), pp.341~353 (2017), 대한심장학회
  47. Biegstraaten M, "Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease : the European Fabry Working Group consensus document", Orphanet J Rare Dis, 10, pp.36~ (2015)
  48. Judge DP, "Use of genetics in the clinical evaluation of cardiomyopathy", JAMA, 302, pp.2471~2476 (2009)
  49. Skrzynia C, "Genetics and heart failure : a concise guide for the clinician", Curr Cardiol Rev, 11, pp.10~17 (2015)
  50. Hershberger RE, "Genetic evaluation of cardiomyopathy : a Heart Failure Society of America Practice Guideline", J Card Fail, 24, pp.281~302 (2018)
  51. Maron BJ, "Contemporary definitions and classification of the cardiomyopathies : an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention", Circulation, 113, pp.1807~1816 (2006)
  52. Elliott P, "Classification of the cardiomyopathies : a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases", Eur Heart J, 29, pp.270~276 (2008)
  53. Arbustini E, "The MOGE(S)classification of cardiomyopathy for clinicians", J Am Coll Cardiol, 64, pp.304~318 (2014)
  54. Cohn JN, "Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study", N Engl J Med, 314, pp.1547~1552 (1986)
  55. Swedberg K, "Ivabradine and outcomes in chronic heart failure(SHIFT) : a randomised placebo-controlled study", Lancet, 376, pp.875~885 (2010)
  56. McMurray JJ, "Angiotensin-neprilysin inhibition versus enalapril in heart failure", N Engl J Med, 371, pp.993~1004 (2014)
  57. CONSENSUS Trial Study Group, "Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)", N Engl J Med, 316, pp.1429~1435 (1987)
  58. SOLVD Investigators, "Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure", N Engl J Med, 325, pp.293~302 (1991)
  59. Packer M, "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group", N Engl J Med, 334, pp.1349~1355 (1996)
  60. Pitt B, "The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators", N Engl J Med, 341, pp.709~717 (1999)
  61. Packer M, "Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group", Circulation, 100, pp.2312~2318 (1999)
  62. Granger CB, "Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors : the CHARM-Alternative trial", Lancet, 362, pp.772~776 (2003)
  63. Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
  64. Marso SP, "Liraglutide and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 375, pp.311~322 (2016)
  65. Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes", N Engl J Med, 377, pp.644~657 (2017)
  66. Ridker PM, "Antiinflammatory therapy with canakinumab for atherosclerotic disease", N Engl J Med, 377, pp.1119~1131 (2017)
  67. Stephen D. Wiviott, "Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes", New England Journal of Medicine, 380(4), pp.347~357 (2019), Massachusetts Medical Society[DOI]
  68. Maurer MS, "Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy", N Engl J Med, 379, pp.1007~1016 (2018)
  69. Moss AJ, "Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators", N Engl J Med, 335, pp.1933~1940 (1996)
  70. Buxton AE, "A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators", N Engl J Med, 341, pp.1882~1890 (1999)
  71. Moss AJ, "Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction", N Engl J Med, 346, pp.877~883 (2002)
  72. Kadish A, "Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy", N Engl J Med, 350, pp.2151~2158 (2004)
  73. Hohnloser SH, "Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction", N Engl J Med, 351, pp.2481~2488 (2004)
  74. Bardy GH, "Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure", N Engl J Med, 352, pp.225~237 (2005)
  75. Kober L, "Defibrillator implantation in patients with nonischemic systolic heart failure", N Engl J Med, 375, pp.1221~1230 (2016)
  76. Olgin JE, "Wearable cardioverter-defibrillator after myocardial infarction", N Engl J Med, 379, pp.1205~1215 (2018)
  77. Bristow MR, "Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure", N Engl J Med, 350, pp.2140~2150 (2004)
  78. Cleland JG, "The effect of cardiac resynchronization on morbidity and mortality in heart failure", N Engl J Med, 352, pp.1539~1549 (2005)
  79. Linde C, "Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms", J Am Coll Cardiol, 52, pp.1834~1843 (2008)
  80. Moss AJ, "Cardiac-resynchronization therapy for the prevention of heart-failure events", N Engl J Med, 361, pp.1329~1338 (2009)
  81. Tang AS, "Cardiac-resynchronization therapy for mild-to-moderate heart failure", N Engl J Med, 363, pp.2385~2395 (2010)
  82. Rose EA, "Long-term use of a left ventricular assist device for end-stage heart failure", N Engl J Med, 345, pp.1435~1443 (2001)
  83. Miller LW, "Use of a continuous-flow device in patients awaiting heart transplantation", N Engl J Med, 357, pp.885~896 (2007)
  84. Slaughter MS, "Advanced heart failure treated with continuous-flow left ventricular assist device", N Engl J Med, 361, pp.2241~2251 (2009)
  85. Rogers JG, "Intrapericardial left ventricular assist device for advanced heart failure", N Engl J Med, 376, pp.451~460 (2017)
  86. Mehra MR, "A fully magnetically levitated circulatory pump for advanced heart failure", N Engl J Med, 376, pp.440~450 (2017)
  87. Velazquez EJ, "Coronary-artery bypass surgery in patients with ischemic cardiomyopathy", N Engl J Med, 374, pp.1511~1520 (2016)
  88. Andreassen AK, "Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients : a randomized trial", Am J Transplant, 14, pp.1828~1838 (2014)
  89. Ardehali A, "Ex-vivo perfusion of donor hearts for human heart transplantation(PROCEED II) : a prospective, open-label, multicentre, randomised non-inferiority trial", Lancet, 385, pp.2577~2584 (2015)
  90. Ferrari R, "Heart failure: an historical perspective", Eur Heart J, 18(Suppl G), pp.G3~G10 (2016)
  91. Flather MD, "Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group", Lancet, 355, pp.1575~1581 (2000)
  92. Bristow MR, "Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators", Circulation, 94, pp.2807~2816 (1996)
  93. Heidenreich PA, "Effect of beta-blockade on mortality in patients with heart failure : a meta-analysis of randomized clinical trials", J Am Coll Cardiol, 30, pp.27~34 (1997)
  94. 최기홍, "The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction", The Korean Journal of Internal Medicine, 34(5), pp.1030~1039 (2019), 대한내과학회[DOI]
  95. Pitt B, "Mineralocorticoid receptor antagonists in patients with heart failure : current experience and future perspectives", Eur Heart J Cardiovasc Pharmacother, 3, pp.48~57 (2017)
  96. McMurray JJ, "Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors : the CHARM-Added trial", Lancet, 362, pp.767~771 (2003)
  97. Gun Ha Park, "Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience", The Korean Journal of Internal Medicine, 33(3), pp.561~567 (2018), 대한내과학회[DOI]
  98. Felker GM, "Tolvaptan in patients hospitalized with acute heart failure : rationale and design of the TACTICS and the SECRET of CHF trials", Circ Heart Fail, 8, pp.997~1005 (2015)
  99. Konstam MA, "Short-term effects of tolvaptan in patients with acute heart failure and volume overload", J Am Coll Cardiol, 69, pp.1409~1419 (2017)
  100. Dominik Berliner, "Current Drug Therapy in Chronic Heart Failure: the New Guidelines of the European Society of Cardiology (ESC)", Korean Circulation Journal, 47(5), pp.543~554 (2017), 대한심장학회[DOI]
  101. Lytvyn Y, "Sodium glucose cotransporter-2 inhibition in heart failure : potential mechanisms, clinical applications, and summary of clinical trials", Circulation, 136, pp.1643~1658 (2017)
  102. Ahmed HM, "Cardioprotective anti-hyperglycaemic medications : a review of clinical trials", Eur Heart J, 39, pp.2368~2375 (2018)
  103. Verma S, "Empagliflozin increases cardiac energy production in diabetes : novel translational insights into the heart failure benefits of SGLT2 inhibitors", JACC Basic Transl Sci, 3, pp.575~587 (2018)
  104. Zelniker TA, "Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes : JACC state-of-the-art review", J Am Coll Cardiol, 72, pp.1845~1855 (2018)
  105. Cavender MA, "SGLT-2inhibitors and cardiovascular risk : an analysis of CVD-REAL", J Am Coll Cardiol, 71, pp.2497~2506 (2018)
  106. Kosiborod M, "Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs : the CVD-REAL 2 study", J Am Coll Cardiol, 71, pp.2628~2639 (2018)
  107. Byrne NJ, "Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure", JACC Basic Transl Sci, 2, pp.347~354 (2017)
  108. Custodio JS Jr, "SGLT2 inhibition and heart failure-current concepts", Heart Fail Rev, 23, pp.409~418 (2018)
  109. Varian K, "Therapeutic strategies targeting inherited cardiomyopathies", Curr Heart Fail Rep, 14, pp.321~330 (2017)
  110. Jacoby D, "Reduction in left ventricular outflow tract gradient with mavacamten (Myk-461) in symptomatic obstructive hypertrophic cardiomyopathy patients (PIONEER-HCM)", J Am Coll Cardiol, 71(11 Suppl), pp.A644~ (2018)
  111. Teerlink JR, "Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure : the ATOMIC-AHF study", J Am Coll Cardiol, 67, pp.1444~1455 (2016)
  112. Teerlink JR, "Chronic oral study of myosin activation to increase contractility in heart failure(COSMIC-HF) : a phase 2, pharmacokinetic, randomised, placebo-controlled trial", Lancet, 388, pp.2895~2903 (2016)
  113. Kaplinsky E, "Cardiac myosin activators for heart failure therapy : focus on omecamtiv mecarbil", Drugs Context, 7, pp.212518~ (2018)
  114. Bartekova M, "Role of cytokines and inflammation in heart function during health and disease", Heart Fail Rev, 23, pp.733~758 (2018)
  115. Van Tassell BW, "Interleukin-1blockade in recently decompensated systolic heart failure : results from REDHART(Recently Decompensated Heart Failure Anakinra Response Trial)", Circ Heart Fail, 10, pp.e004373~ (2017)
  116. Van Tassell BW, "Interleukin-1blockade in heart failure with preserved ejection fraction : rationale and design of the Diastolic Heart Failure Anak inra Response Trial 2(D-HART2)", Clin Cardiol, 40, pp.626~632 (2017)
  117. Van Tassell BW, "Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3(VCU-ART3) : a randomized, placebo-controlled, double-blinded, multicenter study", Clin Cardiol, 41, pp.1004~1008 (2018)
  118. Gabisonia K, "Gene therapy for heart failure : new perspectives", Curr Heart Fail Rep, 15, pp.340~349 (2018)
  119. Greenberg B, "Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease(CUPID 2) : a randomised, multinational, double-blind, placebo-controlled, phase 2b trial", Lancet, 387, pp.1178~1186 (2016)
  120. Hulot JS, "Gene therapy for the treatment of heart failure : promise postponed", Eur Heart J, 37, pp.1651~1658 (2016)
  121. Poglajen G, "Stem cell therapy for chronic heart failure", Curr Opin Cardiol, 30, pp.301~310 (2015)
  122. Tompkins BA, "Comparison of mesenchymal stem cell efficacy in ischemic versus nonischemic dilated cardiomyopathy", J Am Heart Assoc, 7, pp.e008460~ (2018)
  123. Misun Park, "Cardiac Regeneration with Human Pluripotent Stem Cell-Derived Cardiomyocytes", Korean Circulation Journal, 48(11), pp.974~988 (2018), 대한심장학회
  124. 박규환, "Effectiveness of Implantable Cardioverter-Defibrillator Therapy for Heart Failure Patients according to Ischemic or Non-Ischemic Etiology in Korea", Korean Circulation Journal, 47(1), pp.72~81 (2017), 대한심장학회
  125. Writing Committee members, "2013 ACCF", AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation, Circulation, pp.2013, 128[DOI]
  126. Al-Khatib SM, "2017AHA", ACC, American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society, pp.J Am Coll Cardiol, 2018[DOI]
  127. Normand C, "Indications for cardiac resynchronization therapy : a comparison of the major international guidelines", JACC Heart Fail, 6, pp.308~316 (2018)
  128. Leyva F, "Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance", J Cardiovasc Magn Reson, 13, pp.29~ (2011)
  129. Khan FZ, "Targeted left ventricular lead placement to guide cardiac resynchronization therapy : the TARGET study : a randomized, controlled trial", J Am Coll Cardiol, 59, pp.1509~1518 (2012)
  130. Sommer A, "Multimodality imaging-guided left ventricular lead placement in cardiac resynchronization therapy : a randomized controlled trial", Eur J Heart Fail, 18, pp.1365~1374 (2016)
  131. Syeda Atiqa Batul, "Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times", Korean Circulation Journal, 47(5), pp.644~662 (2017), 대한심장학회[DOI]
  132. Marrouche NF, "Catheter ablation for atrial fibrillation with heart failure", N Engl J Med, 378, pp.417~427 (2018)
  133. Di Biase L, "Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device : results from the AATAC multicenter randomized trial", Circulation, 133, pp.1637~1644 (2016)
  134. Tofield A., "The CABANA trial : a first glance at an important study", Eur Heart J, 39, pp.2767~2768 (2018)
  135. Brignole M, "A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS", Eur Heart J, 39, pp.3999~4008 (2018)
  136. Abraham WT, "Wireless pulmonary artery haemodynamic monitoring in chronic heart failure : a randomised controlled trial", Lancet, 377, pp.658~666 (2011)
  137. Givertz MM, "Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction", J Am Coll Cardiol, 70, pp.1875~1886 (2017)
  138. Hindricks G, "Implant-based multiparameter telemonitoring of patients with heart failure(IN-TIME) : a randomised controlled trial", Lancet, 384, pp.583~590 (2014)
  139. Crossley GH, "The CONNECT(Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision)trial : the value of wireless remote monitoring with automatic clinician alerts", J Am Coll Cardiol, 57, pp.1181~1189 (2011)
  140. Parthiban N, "Remote monitoring of implantable cardioverter-defibrillators : a systematic review and meta-analysis of clinical outcomes", J Am Coll Cardiol, 65, pp.2591~2600 (2015)
  141. Whellan DJ, "Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations : results from PARTNERS HF(Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure)study", J Am Coll Cardiol, 55, pp.1803~1810 (2010)
  142. Bohm M, "Fluid status telemedicine alerts for heart failure : a randomized controlled trial", Eur Heart J, 37, pp.3154~3163 (2016)
  143. Boehmer JP, "A multisensor algorithm predicts heart failure events in patients with implanted devices : results from the MultiSENSE study", JACC Heart Fail, 5, pp.216~225 (2017)
  144. Goliasch G, "Refining the prognostic impact of functional mitral regurgitation in chronic heart failure", Eur Heart J, 39, pp.39~46 (2018)
  145. Michler RE, "Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation", N Engl J Med, 374, pp.1932~1941 (2016)
  146. Nishimura RA, "2014 AHA", ACC guideline for the management of patients with valvular heart disease : executive summary : a report of the American College of Cardiology, J Am Coll Cardiol, pp.2014, 63[DOI]
  147. Feldman T, "Percutaneous leaflet repair and annuloplasty for mitral regurgitation", J Am Coll Cardiol, 57, pp.529~537 (2011)
  148. Obadia JF, "Percutaneous repair or medical treatment for secondary mitral regurgitation", N Engl J Med, 379, pp.2297~2306 (2018)
  149. Stone GW, "Transcatheter mitral-valve repair in patients with heart failure", N Engl J Med, 379, pp.2307~2318 (2018)
  150. Messika-Zeitoun D, "Transcatheter mitral valve repair for functional mitral regurgitation using the cardioband system: 1 year outcomes", Eur Heart J (2018)
  151. De Backer O, "Percutaneous transcatheter mitral valve replacement : an overview of devices in preclinical and early clinical evaluation", Circ Cardiovasc Interv, 7, pp.400~409 (2014)
  152. Regueiro A, "Transcatheter mitral valve replacement : insights from early clinical experience and future challenges", J Am Coll Cardiol, 69, pp.2175~2192 (2017)
  153. ) : a phase 2, randomized, sham-controlled trial, "Circulation", 2018, 364~375
  154. Shah SJ, "One-year safety and clinical outcomes of a transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction in the reduce elevated left atrial pressure in patients with heart failure(REDUCE LAP-HF I)trial : a randomized clinical trial", JAMA Cardiol, 3, pp.968~977 (2018)
  155. Michael Böhm, "Renal Denervation for Chronic Heart Failure: Background and Pathophysiological Rationale", Korean Circulation Journal, 47(1), pp.9~15 (2017), 대한심장학회
  156. Zannad F, "Chronic vagal stimulation for the treatment of low ejection fraction heart failure : results of the NEural Cardiac TherApy foR Heart Failure(NECTAR-HF)randomized controlled trial", Eur Heart J, 36, pp.425~433 (2015)
  157. De Ferrari GM, "Long-term vagal stimulation for heart failure : eighteen month results from the NEural Cardiac TherApy foR Heart Failure(NECTAR-HF)trial", Int J Cardiol, 244, pp.229~234 (2017)
  158. Gold MR, "Vagus nerve stimulation for the treatment of heart failure : the INOVATE-HF trial", J Am Coll Cardiol, 68, pp.149~158 (2016)
  159. Bhatt DL, "A controlled trial of renal denervation for resistant hypertension", N Engl J Med, 370, pp.1393~1401 (2014)
  160. Coppolino G, "Renal denervation for resistant hypertension", Cochrane Database Syst Rev, 2, pp.CD011499~ (2017)
  161. Townsend RR, "Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications(SPYRAL HTN-OFF MED) : a randomised, sham-con-trolled, proof-of-concept trial", Lancet, 390, pp.2160~2170 (2017)
  162. Teuteberg JJ, "The HVAD left ventricular assist device : risk factors for neurological events and risk mitigation strategies", JACC Heart Fail, 3, pp.818~828 (2015)
  163. Strueber M, "Results of the post-market registry to evaluate the HeartWare left ventricular assist system(ReVOLVE)", J Heart Lung Transplant, 33, pp.486~491 (2014)
  164. Chatterjee A, "Clinical overview of the HVAD : a centrifugal continuous-flow ventricular assist device with magnetic and hydrodynamic bearings including lateral implantation strategies", J Thorac Dis, 10, pp.S1785~S1789 (2018)
  165. Mehra MR, "Two-year outcomes with a magnetically levitated cardiac pump in heart failure", N Engl J Med, 378, pp.1386~1395 (2018)
  166. Cohn WE, "Total artificial hearts : past, present, and future", Nat Rev Cardiol, 12, pp.609~617 (2015)
  167. Wells D, "The 50", 50 cc total artificial heart trial : extending the benefits of the total artificial heart to underserved populations, 2017, pp.20, 16~19
  168. 이해영, "Initial Report of the Korean Organ Transplant Registry (KOTRY): Heart Transplantation", Korean Circulation Journal, 47(6), pp.868~876 (2017), 대한심장학회[DOI]
  169. Kittleson MM, "Long-term care of the heart transplant recipient", Curr Opin Organ Transplant, 19, pp.515~524 (2014)
  170. Kobashigawa JA, "Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes", J Heart Lung Transplant, 29, pp.504~508 (2010)
  171. 김인철, "The Past, Present and Future of Heart Transplantation", Korean Circulation Journal, 48(7), pp.565~590 (2018), 대한심장학회[DOI]
  172. Crespo-Leiro MG, "Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation : CARGO II", Eur Heart J, 37, pp.2591~2601 (2016)
  173. Zaroff JG, "Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, VA", Circulation, 106, pp.836~841 (2002)
  174. Lee SE, "A multicentre cohort study of acute heart failure syndromes in Korea : rationale, design, and interim observations of the Korean Acute Heart Failure(KorAHF)registry", Eur J Heart Fail, 16, pp.700~708 (2014)
  175. 최동주, "Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure: A Report From the Korean Heart Failure Registry", Korean Circulation Journal, 41(7), pp.363~371 (2011), 대한심장학회
  176. Sato N, "Clinical features and outcome in hospitalized heart failure in Japan(from the ATTEND registry)", Circ J, 77, pp.944~951 (2013)
  177. Fonarow GC, "Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004 : findings from Acute Decompensated Heart Failure National Registry(ADHERE)", Am Heart J, 153, pp.1021~1028 (2007)
  178. Abraham WT, "Predictors of in-hospital mortality in patients hospitalized for heart failure : insights from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure(OPTIMIZE-HF)", J Am Coll Cardiol, 52, pp.347~356 (2008)
  179. Nieminen MS, "EuroHeart Failure Survey II(EHFS II) : a survey on hospitalized acute heart failure patients : description of population", Eur Heart J, 27, pp.2725~2736 (2006)
  180. Spinar J, "Baseline characteristics and hospital mortality in the Acute Heart Failure Database(AHEAD)main registry", Crit Care, 15, pp.R291~ (2011)
  181. Parenica J, "Long-term survival following acute heart failure : the Acute Heart Failure Database Main registry(AHEAD main)", Eur J Intern Med, 24, pp.151~160 (2013)
  182. Packer M, "Acute heart failure is an event rather than a disease : plea for a radical change in thinking and in therapeutic drug development", JACC Heart Fail, 6, pp.73~75 (2018)
  183. Pieter Martens, "How to tackle congestion in acute heart failure", The Korean Journal of Internal Medicine, 33(3), pp.462~473 (2018), 대한내과학회[DOI]
  184. Filippatos G, "An introduction to acute heart failure syndromes : definition and classification", Heart Fail Rev, 12, pp.87~90 (2007)
  185. Nieminen MS, "Executive summary of the guidelines on the diagnosis and treatment of acute heart failure : the Task Force on Acute Heart Failure of the European Society of Cardiology", Eur Heart J, 26, pp.384~416 (2005)
  186. Gheorghiade M, "Acute heart failure syndromes : current state and framework for future research", Circulation, 112, pp.3958~3968 (2005)
  187. Nohria A, "Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure", J Am Coll Cardiol, 41, pp.1797~1804 (2003)
  188. Kamilė Čerlinskaitė, "Acute Heart Failure Management", Korean Circulation Journal, 48(6), pp.463~480 (2018), 대한심장학회[DOI]
  189. Matsue Y, "Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure", J Am Coll Cardiol, 69, pp.3042~3051 (2017)
  190. Park JJ, "The effect of door-to-diuretic time on clinical outcomes in patients with acute heart failure", JACC Heart Fail, 6, pp.286~294 (2018)
  191. O'Connor CM, "Effect of nesiritide in patients with acute decompensated heart failure", N Engl J Med, 365, pp.32~43 (2011)
  192. Teerlink JR, "Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure(RELAX-AHF) : a randomised, placebo-controlled trial", Lancet, 381, pp.29~39 (2013)
  193. "Efficacy, safety and tolerability of serelaxin when added to standard therapy in AHF (RELAX-AHF-2)" (2013)[URL]
  194. Packer M, "Effect of ularitide on cardiovascular mortality in acute heart failure", N Engl J Med, 376, pp.1956~1964 (2017)
  195. Moiseyev VS, "A randomized, placebo-controlled, double-blind study(RUSSLAN)", Eur Heart J, 23, pp.1422~1432 (2002)
  196. Mebazaa A, "Levosimendan vs dobutamine for patients with acute decompensated heart failure : the SURVIVE randomized trial", JAMA, 297, pp.1883~1891 (2007)
  197. Velazquez EJ, "Angiotensin-neprilysin inhibition in acute decompensated heart failure", N Engl J Med (2018)
  198. O'Connor CM, "High heart failure readmission rates: is it the health system's fault?", JACC Heart Fail, 5, pp.393~ (2017)
  199. Gupta A, "Association of the hospital readmissions reduction program implementation with readmission and mortality outcomes in heart failure", JAMA Cardiol, 3, pp.44~53 (2018)
  200. Pandey A, "Association of 30-day readmission metric for heart failure under the hospital readmissions reduction program with quality of care and outcomes", JACC Heart Fail, 4, pp.935~946 (2016)
  201. Wadhera RK, "30-Day episode payments and heart failure outcomes among medicare beneficiaries", JACC Heart Fail, 6, pp.379~387 (2018)
  202. Gupta A, "The hospital readmissions reduction program-learning from failure of a healthcare policy", Eur J Heart Fail, 20, pp.1169~1174 (2018)
  203. Johnson KW, "Artificial intelligence in cardiology", J Am Coll Cardiol, 71, pp.2668~2679 (2018)
  204. Ahmad T, "Machine learning methods improve prognostication, identify clinically distinct phenotypes, and detect heterogeneity in response to therapy in a large cohort of heart failure patients", J Am Heart Assoc, 7, pp.e008081~ (2018)

관련 논문AI추천

Current status of heart failure: global and KoreaDong-Ju Choi, Jin Joo Park대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제3호좌심실 수축 기능 저하 심부전증의 치료박진주, 최동주대한내과학회 · 대한내과학회지2015 · 제88권 제2호Update on heart failure management and future directions박명수, 윤종찬, 최홍미대한내과학회 · The Korean Journal of Internal Medicine2019 · 제34권 제4호Advanced heart failure: a contemporary approach강석민, Kyeong-Hyeon Chun대한내과학회 · The Korean Journal of Internal Medicine2023 · 제38권 제4호Heart failure with preserved ejection fraction: insights from recent clinical researchesMi-Na Kim, Seong-Mi Park대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제3호급성 심부전의 혈역학적 감시와 치료박철수대한중환자의학회 · Acute and Critical Care2011 · 제26권 제1호

이 간행물의 다른 논문 (27건)

Current status of acute myocardial infarction in Korea김영조, 조명찬, 김용철, 김종진, 안영근, 정명호pp. 1-10Management plans for populations with normal-to-hypertensive blood pressures: risks and benefits of antihypertensive drug treatment in populations previously defined as having high-normal blood pressure박성하pp. 44-49Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer안명주, 임성원pp. 50-59Fecal calprotectin in daily practice for patients with inflammatory bowel disease: where do we stand in Korea?차재명pp. 60-62Microbiological and genotypic factors affecting mortality in methicillin-resistant Staphylococcus aureus bacteremia주은정pp. 63-64
원문 보기